about
sameAs
Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agentsIrod/Ian5: an inhibitor of gamma-radiation- and okadaic acid-induced apoptosisDiscovery and development of the Polo-like kinase inhibitor volasertib in cancer therapyRituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patientsElevated monocyte phosphorylated p38 in nearby employees after a chemical explosionCorrelation analysis of two-dimensional gel electrophoretic protein patterns and biological variables.Gel2DE - a software tool for correlation analysis of 2D gel electrophoresis data.How should clinical data be included in experimental studies of cancer immunology?In vivo optical imaging of acute myeloid leukemia by green fluorescent protein: time-domain autofluorescence decoupling, fluorophore quantification, and localization.Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia.Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells.Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival.Untangling the intracellular signalling network in cancer--a strategy for data integration in acute myeloid leukaemia.Clinical proteomics of myeloid leukemia.Cellular stress induced by resazurin leads to autophagy and cell death via production of reactive oxygen species and mitochondrial impairmentCaspase-dependent, geldanamycin-enhanced cleavage of co-chaperone p23 in leukemic apoptosis.Use of marine toxins in combination with cytotoxic drugs for induction of apoptosis in acute myelogenous leukaemia cells.Single cell profiling of potentiated phospho-protein networks in cancer cells.Expression of TP53 isoforms p53β or p53γ enhances chemosensitivity in TP53(null) cell lines.Up-regulation of anti-apoptotic genes confers resistance to the novel anti-leukaemic compound PEP005 in primary AML cellsAnalysis of acute myelogenous leukemia: preparation of samples for genomic and proteomic analyses.Functional p53 is required for rapid restoration of daunorubicin-induced lesions of the spleenDistinct single cell signal transduction signatures in leukocyte subsets stimulated with khat extract, amphetamine-like cathinone, cathine or norephedrineSIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells.First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma.Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulationSpecific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemiaTargeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro.Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells.The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.Animal models of acute myelogenous leukaemia - development, application and future perspectives.8-Chloro-cAMP induces apoptotic cell death in a human mammary carcinoma cell (MCF-7) line.Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies.Immunotherapy in chronic lymphocytic leukemia.Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukemia?Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targets for novel antileukaemic therapy.Interactions of the natural product (+)-avrainvillamide with nucleophosmin and exportin-1 Mediate the cellular localization of nucleophosmin and its AML-associated mutants.Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML.
P50
Q24633763-EC9818A3-30D4-4BE0-9410-8226454C90E2Q24682548-74D33B46-7AE3-41C9-B68A-D486C3392E25Q26991736-AE29B90C-62F5-4E87-A634-01987DAAE2DDQ28255301-F8A19765-2A53-49EB-BE26-6A7B7AC2974FQ28831248-34ABFCC2-2F98-480C-A1BA-69F7E3274971Q30477879-40FA4605-10B4-436D-8B4A-C5A4CBE57B2CQ30653614-DFE2D361-BD95-4A0E-8DE1-A3AB9D9E022CQ30919748-3B01AB74-D038-41E4-BEE5-FEECB46D1F00Q33285979-D41CD1B1-0F80-4594-8E67-01E24B94DA9DQ33415379-E15C065D-51A8-4155-AA72-B242FAF26FB3Q33629475-580019CA-AEA3-46A1-AFA9-7A73F9BFABC9Q33667156-E4BD6A55-B0C7-4CBB-9DB4-7FC8F125A117Q33746148-49C523D9-C880-4A12-BC57-8D325726DE46Q33999524-190F6AEF-480C-4FBA-977B-2D8487A7BACAQ34158794-C050331D-9D52-41A3-9656-406454DB4604Q34358774-FAB0A079-A3D4-4AB6-9E77-D71E65295A79Q34534299-592D6E66-15CD-4F2E-B6D3-790D2F6BCEC5Q34549433-381BF985-8BEC-42BC-A678-2F4B0A2C678DQ34586799-B0A12241-A1DB-492F-B012-0389B604CC66Q34781362-DE8C1742-4820-47A2-AD87-8A056249BF86Q34787226-3CED6021-7F6C-4CE7-9C8D-583535D3A1E4Q34810055-E85FAD24-44D2-44D6-98BD-C514B146B1B9Q34812762-3CA81692-695C-4B1A-8E58-DC77E13C6B3FQ35009327-F5F83EB4-05C3-49CD-A680-CBD5D2AFEBB5Q35110920-100EE9A6-6B91-4C5B-9294-1040AED333B7Q35194464-39DA0314-A0DA-47DD-B039-AD04CE296746Q35550103-FFD1D77E-D349-42B7-83F8-00F3A9AAA72BQ35664342-B25261DB-3F47-477D-AFF2-725B25E7DE68Q35750567-D0682392-4961-44B2-9892-EE4F8A8851A3Q35808591-B2D95494-9D97-4004-89B7-E1824875E96BQ35808597-072AA272-EEF1-4BF5-96E3-7DDF53CA544DQ36063233-A17D2B8A-097E-44CB-BB4F-8A8BF0A809BEQ36066980-96744D7C-D544-424D-9094-852BE5037424Q36081387-FE685366-C504-42C2-9B71-8C29AB4CB944Q36173125-6F24F881-2FAE-4F7A-A855-82993565324EQ36185210-0D721BAB-6703-4A0A-B8C0-88F3AAEBFFB6Q36202298-9C8B3C68-F631-44C8-80BB-D6F71997FA95Q36264792-307594DB-C7D6-42CA-A48F-CC9145EC0076Q36298896-D22977C7-56C9-45DA-8515-1306772540A9Q36379368-040B5A7C-C24B-4CE1-8EF8-18B8963F9393
P50
description
Noors onderzoeker
@nl
norsk forsker
@nb
researcher
@en
հետազոտող
@hy
name
Bjørn Tore Gjertsen
@ast
Bjørn Tore Gjertsen
@en
Bjørn Tore Gjertsen
@es
Bjørn Tore Gjertsen
@nb
Bjørn Tore Gjertsen
@nl
Bjørn Tore Gjertsen
@sl
type
label
Bjørn Tore Gjertsen
@ast
Bjørn Tore Gjertsen
@en
Bjørn Tore Gjertsen
@es
Bjørn Tore Gjertsen
@nb
Bjørn Tore Gjertsen
@nl
Bjørn Tore Gjertsen
@sl
altLabel
Bjorn Tore Gjertsen
@ast
Bjorn Tore Gjertsen
@en
Bjorn Tore Gjertsen
@es
Bjorn Tore Gjertsen
@nl
prefLabel
Bjørn Tore Gjertsen
@ast
Bjørn Tore Gjertsen
@en
Bjørn Tore Gjertsen
@es
Bjørn Tore Gjertsen
@nb
Bjørn Tore Gjertsen
@nl
Bjørn Tore Gjertsen
@sl
P106
P21
P2287
P27
P31
P496
0000-0001-9358-9704
P569
1966-01-01T00:00:00Z